与阿法替尼治疗相关的双侧角膜炎

IF 1 Q4 OPHTHALMOLOGY
Ya-Tung Liu, Chen-Wei Lin, Chi-Chin Sun, Shih-Chieh Shao, Nan-Ni Chen
{"title":"与阿法替尼治疗相关的双侧角膜炎","authors":"Ya-Tung Liu, Chen-Wei Lin, Chi-Chin Sun, Shih-Chieh Shao, Nan-Ni Chen","doi":"10.4103/tjo.tjo-d-24-00003","DOIUrl":null,"url":null,"abstract":"\n This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old, stage IV nasopharyngeal carcinoma male patient, who was under afatinib treatment and had experienced progressive bilateral eye dryness and tenderness on increasing afatinib from 40 mg every other day to 40 mg daily. Clinical examination noted bilateral visual acuity reduction, diffuse superficial punctate keratopathy in the right eye, and a central epithelial defect in the left eye. Seidel test results were negative for both eyes, with no corneal infiltration, lagophthalmos, anterior chamber cell precipitation, or retinal lesion. Symptoms subsequently resolved after reducing the frequency of afatinib used, along with intensive ocular hydration. In summary, this case highlighted afatinib’s potential link to bilateral keratitis, and early afatinib dose adjustment with supportive medication could significantly reverse the condition.","PeriodicalId":44978,"journal":{"name":"Taiwan Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bilateral keratitis associated with afatinib therapy\",\"authors\":\"Ya-Tung Liu, Chen-Wei Lin, Chi-Chin Sun, Shih-Chieh Shao, Nan-Ni Chen\",\"doi\":\"10.4103/tjo.tjo-d-24-00003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old, stage IV nasopharyngeal carcinoma male patient, who was under afatinib treatment and had experienced progressive bilateral eye dryness and tenderness on increasing afatinib from 40 mg every other day to 40 mg daily. Clinical examination noted bilateral visual acuity reduction, diffuse superficial punctate keratopathy in the right eye, and a central epithelial defect in the left eye. Seidel test results were negative for both eyes, with no corneal infiltration, lagophthalmos, anterior chamber cell precipitation, or retinal lesion. Symptoms subsequently resolved after reducing the frequency of afatinib used, along with intensive ocular hydration. In summary, this case highlighted afatinib’s potential link to bilateral keratitis, and early afatinib dose adjustment with supportive medication could significantly reverse the condition.\",\"PeriodicalId\":44978,\"journal\":{\"name\":\"Taiwan Journal of Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Taiwan Journal of Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/tjo.tjo-d-24-00003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Taiwan Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tjo.tjo-d-24-00003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本病例讨论了阿法替尼(一种不可逆的表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI))可能诱发的严重眼部副作用--双侧角膜炎。我们对一名 52 岁的 IV 期鼻咽癌男性患者的病情进展进行了探讨。该患者正在接受阿法替尼治疗,在将阿法替尼从每隔一天服用 40 毫克增加到每天服用 40 毫克后,出现了进行性的双侧眼睛干涩和触痛。临床检查发现双侧视力下降,右眼出现弥漫性浅表点状角膜病变,左眼出现中央上皮缺损。两只眼睛的 Seidel 试验结果均为阴性,没有角膜浸润、眼睑下垂、前房细胞沉淀或视网膜病变。在减少阿法替尼的使用频率并加强眼部补水后,症状随之缓解。总之,本病例强调了阿法替尼与双侧角膜炎的潜在联系,及早调整阿法替尼剂量并使用支持性药物可显著逆转病情。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bilateral keratitis associated with afatinib therapy
This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old, stage IV nasopharyngeal carcinoma male patient, who was under afatinib treatment and had experienced progressive bilateral eye dryness and tenderness on increasing afatinib from 40 mg every other day to 40 mg daily. Clinical examination noted bilateral visual acuity reduction, diffuse superficial punctate keratopathy in the right eye, and a central epithelial defect in the left eye. Seidel test results were negative for both eyes, with no corneal infiltration, lagophthalmos, anterior chamber cell precipitation, or retinal lesion. Symptoms subsequently resolved after reducing the frequency of afatinib used, along with intensive ocular hydration. In summary, this case highlighted afatinib’s potential link to bilateral keratitis, and early afatinib dose adjustment with supportive medication could significantly reverse the condition.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.80
自引率
9.10%
发文量
68
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信